Thomas M. Habermann

39.1k total citations · 3 hit papers
547 papers, 19.6k citations indexed

About

Thomas M. Habermann is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Thomas M. Habermann has authored 547 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 421 papers in Pathology and Forensic Medicine, 230 papers in Oncology and 180 papers in Genetics. Recurrent topics in Thomas M. Habermann's work include Lymphoma Diagnosis and Treatment (416 papers), Chronic Lymphocytic Leukemia Research (162 papers) and Viral-associated cancers and disorders (138 papers). Thomas M. Habermann is often cited by papers focused on Lymphoma Diagnosis and Treatment (416 papers), Chronic Lymphocytic Leukemia Research (162 papers) and Viral-associated cancers and disorders (138 papers). Thomas M. Habermann collaborates with scholars based in United States, Canada and Italy. Thomas M. Habermann's co-authors include Thomas E. Witzig, Tait D. Shanafelt, Jeff A. Sloan, Stephen M. Ansell, David J. Inwards, James R. Cerhan, Colin P. West, Kay M. Ristow, Paul J. Novotny and Joseph C. Kolars and has published in prestigious journals such as New England Journal of Medicine, JAMA and The Journal of Experimental Medicine.

In The Last Decade

Thomas M. Habermann

513 papers receiving 19.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Perceived Medical Errors With Resident Distress and Empathy

2006 1.1k citations Thomas M. Habermann et al. profile →
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

2006 997 citations Thomas M. Habermann, Edie Weller et al. Journal of Clinical Oncology profile →
The well-being of physicians

2003 580 citations Thomas M. Habermann et al. profile →

Peers

Countries citing papers authored by Thomas M. Habermann

Since Specialization

Citations

This map shows the geographic impact of Thomas M. Habermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Habermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Habermann more than expected).

Fields of papers citing papers by Thomas M. Habermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Habermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Habermann. The network helps show where Thomas M. Habermann may publish in the future.

Co-authorship network of co-authors of Thomas M. Habermann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Habermann. A scholar is included among the top collaborators of Thomas M. Habermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Habermann. Thomas M. Habermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy 2024 ·Haematologica ·Aung M. Tun, Yucai Wang, Seth Maliske, Ivana N. Micallef, David J. Inwards, Thomas M. Habermann, Luis F. Porrata, Jonas Paludo, José C. Villasboas, Allison Rosenthal, Mohamed A. Kharfan‐Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston	4
2	Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study 2024 ·Blood ·Jacqueline Wang, Jihao Zhou, (unknown), Han W. Tun, Javier Muñoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, (unknown), Catherine Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang	0
3	Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy 2024 ·Transplantation and Cellular Therapy ·Aung M. Tun, Yucai Wang, Seth Maliske, Ivana N. Micallef, David J. Inwards, Thomas M. Habermann, Luis F. Porrata, Jonas Paludo, José C. Villasboas, Allison Rosenthal, Mohamed A. Kharfan‐Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston	1
4	Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data 2023 ·SHILAP Revista de lepidopterología ·Priyanka A. Pophali, Lindsay M. Morton, Susan K. Parsons, David Hodgson, Gita Thanarajasingam, Carrie A. Thompson, Thomas M. Habermann, Kerry J. Savage	2
5	Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma 2022 ·American Journal of Hematology ·Juan Pablo Alderuccio, Isildinha M. Reis, Thomas M. Habermann, Brian K. Link, Catherine Thiéblemont, Annarita Conconi, Melissa C. Larson, Luciano Cascione, Wei Zhao, James R. Cerhan, Emanuele Zucca, Izidore S. Lossos	12
6	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study 2022 ·Blood Advances ·Aung M. Tun, Arushi Khurana, Raphael Mwangi, Brian K. Link, Yucai Wang, Andrew L. Feldman, Carrie A. Thompson, Anne J. Novak, José C. Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S. Nowakowski, Thomas E. Witzig, Stephen M. Ansell, Lisa M. Rimsza, James R. Cerhan, Thomas M. Habermann, Matthew J. Maurer	7
7	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL) 2021 ·Transplantation and Cellular Therapy ·Arushi Khurana, Matthew Hathcock, Thomas M. Habermann, Abdullah S. Al Saleh, (unknown), Tuan Truong, N. Nora Bennani, Jonas Paludo, José C. Villasboas, (unknown), David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Ivana N. Micallef, Yi Lin	1
8	Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma 2021 ·International Journal of Cancer ·Mark Liebow, Melissa C. Larson, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call, William R. Macon, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	7
9	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes 2021 ·Blood Advances ·Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski	13
10	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	16
11	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era 2018 ·Blood ·Yucai Wang, Umar Farooq, Brian K. Link, Mehrdad Hefazi, Cristine Allmer, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Stephen M. Ansell, James R. Cerhan, Grzegorz S. Nowakowski	1
12	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma 2015 ·Blood ·Thomas E. Witzig, Craig B. Reeder, Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William R. Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Mamta Gupta	83
13	Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 2014 ·Journal of Clinical Oncology ·Brad S. Kahl, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning	138
14	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study 2014 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson, Candido E. Rivera, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Randy D. Gascoyne, Thomas M. Habermann, Thomas E. Witzig	268
15	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) 2012 ·Journal of Clinical Oncology ·Leo I. Gordon, Fangxin Hong, Richard I. Fisher, Nancy L. Bartlett, Joseph M. Connors, Randy D. Gascoyne, Henry Wagner, Patrick J. Stiff, Bruce D. Cheson, Mary Gospodarowicz, Ranjana H. Advani, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning	194
16	Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Jennifer L. Kelly, Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan, Alice H. Wang, Thomas E. Witzig, Timothy G. Call, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	34
17	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494 2010 ·Clinical Cancer Research ·Jane N. Winter, Shuli Li, (unknown), Daina Variakojis, Beverly P. Nelson, Maryla Krajewska, Lijun Zhang, Thomas M. Habermann, Richard I. Fisher, William R. Macon, Mukesh Chhanabhai, Raymond E. Felgar, Eric D. Hsi, L. Jeffrey Medeiros, James K. Weick, Edie Weller, Ari Melnick, John C. Reed, Sandra J. Horning, Randy D. Gascoyne	26
18	Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma 2009 ·Clinical Cancer Research ·Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, (unknown), Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman	263
19	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era 2009 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Matthew J. Maurer, Thomas M. Habermann, Stephen M. Ansell, William R. Macon, Kay M. Ristow, Cristine Allmer, Susan L. Slager, Thomas E. Witzig, James R. Cerhan	45
20	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma 2008 ·Journal of Clinical Oncology ·Peter H. Wiernik, Izidore S. Lossos, Joseph M. Tuscano, Glen R. Justice, Julie M. Vose, Craig E. Cole, Wwt Lam, Kyle McBride, Kenton Wride, Dennis Pietronigro, Kenichi Takeshita, Annette Ervin‐Haynes, Jerome B. Zeldis, Thomas M. Habermann	300

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact